dr
zealand
univers
otago
christchurch
new
zealand
import
streptococcu
pneumonia
pneumonia
pathogen
beyond
question
pneumonia
regard
singl
biggest
caus
communityacquir
pneumonia
across
age
group
geograph
region
world
howev
diagnos
pneumococc
pneumonia
individu
patient
difficult
mainli
due
inabl
obtain
specimen
site
infect
failur
diagnost
test
distinguish
colon
infect
regardless
shortcom
newer
diagnost
enhanc
understand
role
pneumonia
etiolog
pneumonia
sever
way
first
reinforc
import
pneumonia
commonli
identifi
caus
pneumonia
exampl
latest
gener
pneumococc
urinari
antigen
later
flow
test
improv
abil
diagnos
pneumococc
pneumonia
adult
second
measur
pneumococc
load
provid
insight
pathogenesi
pneumonia
may
help
distinguish
colon
infect
particular
preliminari
data
indic
quantit
pcr
test
upper
respiratori
tract
specimen
may
diagnost
util
third
newer
diagnost
increas
recognit
pneumococcu
often
present
potenti
pathogen
observ
reinforc
concept
infect
multipl
pathogen
may
import
pathogenesi
pneumonia
press
need
complet
new
approach
pneumonia
diagnost
particularli
approach
distinguish
colonis
infect
microorgan
distinguish
recent
past
infect
account
host
respons
utilis
sampl
easi
obtain
conflict
interest
v
jn
f
g
pneumonia
studi
g
pathogen
laboratori
fondat
lyon
franc
network
fondat
lyon
franc
background
aim
final
purpos
pilot
multicentr
pneumonia
studi
launch
provid
inform
pneumonia
etiolog
virus
bacteri
improv
case
manag
pneumonia
ill
child
method
hospitalbas
casecontrol
studi
carriedout
center
locat
countri
contin
case
control
year
age
enrol
respiratori
specimen
whole
blood
collect
pneumonia
case
control
identifi
virus
bacteria
use
realtim
multiplex
pcr
assay
streptococcu
pneumonia
serotyp
posit
sampl
result
main
bacteri
agent
found
case
control
respiratori
sampl
pneumonia
respect
staphylococcu
aureu
haemophilu
influenza
b
moraxella
pneumonia
chlamydia
pneumonia
less
repres
viral
popul
rsv
princip
agent
found
case
control
hmpv
influenzaab
found
mainli
case
rhinovirus
found
equal
control
case
around
main
pneumonia
serotyp
repres
viral
pneumonia
serotyp
popul
differ
countri
result
preliminari
nonetheless
interest
conclus
object
studi
identifi
etiolog
pneumonia
among
hospit
children
develop
emerg
countri
result
improv
individu
care
propos
appropri
public
health
polici
result
permit
better
implement
target
cur
prevent
measur
conflict
interest
mc
z
z
cl
r
l
kp
sa
pv
sa
health
scienc
univers
witwatersrand
respiratori
mening
pathogen
unit
johannesburg
south
africa
medicin
stoni
brook
stoni
brook
univers
new
york
usa
advanc
molecular
diagnost
expand
repertoir
respiratori
virus
implic
pathogenesi
pneumonia
aim
determin
preval
human
bocaviru
hbov
human
rhinoviru
hrv
polyomaviruswu
wupyv
ki
kipyv
human
coronavirus
cov
among
children
hospit
lower
respiratori
tract
infect
lrti
probe
role
pneumococc
coinfect
hivinfect
uninfect
children
multiplex
realtim
revers
transcriptasepolymeras
chain
reaction
undertaken
archiv
nasopharyng
aspir
obtain
cohort
children
random
receiv
pneumococc
conjug
vaccin
placebo
hospit
lrti
least
one
newlystudi
virus
identifi
lrtiepisod
hivinfect
uninfect
children
respect
newlystudi
virus
detect
high
frequenc
associ
respiratori
virus
hivinfect
hivuninfect
children
fulli
hivuninfect
children
lower
incid
hospit
kipyv
ci
wupyv
ci
overal
coronavirus
ci
howev
differ
incid
hbov
hrv
placebo
recipi
among
hivuninfect
children
also
differ
incid
pneumonia
hospit
observ
placebo
recipi
among
hivinfect
children
establish
high
preval
newli
studi
virus
hivinfect
hivuninfect
children
hospit
lrti
use
pcvprobe
approach
establish
pneumonia
associ
polyomavirus
coronavirus
probabl
precipit
pneumococc
coinfect
prevent
pcv
immun
conflict
interest
mr
mr
cg
cg
polici
vanderbilt
univers
nashvil
usa
center
immun
respiratori
diseas
center
diseas
control
prevent
atlanta
usa
background
aim
pneumonia
hospit
us
children
age
year
declin
introduct
per
assess
whether
tennesse
pneumonia
trend
similar
whether
declin
continu
follow
introduct
method
tennesse
resid
age
year
pneumonia
reason
admiss
identifi
tennesse
hospit
discharg
data
system
perform
timeseri
analysi
annual
monthli
rate
pneumonia
hospit
compar
observ
annual
rate
expect
rate
base
trend
baselin
year
introduct
pandem
period
exclud
analys
fractur
serv
control
condit
result
pneumonia
hospit
rate
per
tennessean
children
year
repres
declin
confid
interv
expect
rate
base
year
trend
declin
expect
rate
per
base
baselin
trend
figur
declin
repres
approxim
fewer
pneumonia
hospit
expect
annual
base
expect
rate
baselin
year
respect
declin
fractur
conclus
histor
low
pneumonia
hospit
among
young
children
demonstr
earli
benefit
transit
conflict
interest
r
ol
eb
jjc
al
al
nurs
school
nurs
goiania
brazil
medicin
pontifici
cathol
univers
goiania
brazil
commun
health
institut
tropic
patholog
public
health
feder
univers
goia
goiania
brazil
analysi
health
situat
ministri
health
brasilia
brazil
brasilia
brazil
epidemiolog
research
research
educ
institut
hospit
sirioliban
sao
paulo
brazil
commun
health
institut
tropic
patholog
public
health
feder
univers
goia
goiania
brazil
background
communityacquir
pneumonia
lead
caus
mortal
global
particularli
among
infant
elderli
brazil
introduc
routin
immun
target
children
age
month
aim
assess
impact
pneumonia
death
three
year
vaccin
start
method
brazilian
mortal
inform
system
data
use
conduct
interrupt
timeseri
analysi
patient
resid
state
capit
feder
district
pneumonia
death
primari
caus
defin
code
respiratori
caus
death
except
code
use
compar
monthli
denomin
estim
censu
data
prevaccin
period
exclud
pandem
month
use
ascertain
predict
pneumonia
mortal
rate
postvaccin
use
holtwint
method
control
trend
season
variat
monthlyobserv
mortal
rate
pneumonia
compar
group
compar
predict
valu
agegroup
percentag
chang
calcul
ci
respect
pvalu
result
pneumonia
mortal
rate
children
age
month
decreas
ci
postvaccin
period
mortal
due
respiratori
caus
increas
ci
overal
reduct
estim
compar
pneumonia
vs
respiratori
caus
signific
decreas
pneumonia
mortal
observ
agegroup
conclus
find
point
decreas
pneumonia
mortal
rate
infant
target
immun
program
year
vaccin
start
herd
effect
yet
observ
conflict
interest
perch
studi
vaccin
access
center
john
hopkin
bloomberg
school
public
health
baltimor
usa
background
aim
vaccin
probe
studi
shown
obviou
alveolar
consolid
chest
xray
whodefin
chest
xray
confirm
pneumonia
cxrac
associ
pneumococc
haemophilu
influenza
type
b
pneumonia
analysi
assess
diagnost
accuraci
standard
cxr
microbiolog
confirm
pneumococc
pneumonia
mcpp
case
pneumonia
etiolog
research
child
health
perch
studi
method
pneumonia
etiolog
research
child
health
perch
casecontrol
studi
pneumonia
etiolog
among
children
age
month
hospit
whodefin
sever
sever
pneumonia
seven
african
asian
countri
standard
biolog
specimen
test
cxr
obtain
admiss
cxr
dualread
train
panel
pediatrician
radiologist
cxrac
infiltr
normal
arbitr
panel
resolv
discord
read
mcpp
case
posit
streptococcu
pneumonia
cultur
blood
lung
pleural
aspir
lyta
posit
lung
pleural
aspir
sensitivityspecif
cxr
mcpp
calcul
result
overal
case
cxrac
sitespecif
rang
enrol
case
interpret
cxr
find
mcpp
cxrac
infiltr
normal
nonmcpp
case
cxrac
infiltr
normal
cxrac
specif
mcpp
posit
predict
valu
neg
predict
valu
conclus
whodefin
cxrac
associ
pneumococc
pneumonia
perch
studi
howev
approxim
onethird
pneumococc
pneumonia
present
primari
endpoint
pneumonia
pep
conflict
interest
l
access
unit
pfizer
ab
sollentuna
sweden
background
aim
pneumococc
vaccin
infant
part
nation
immun
program
mani
countri
one
two
vaccin
chosen
entir
popul
either
vaccin
vaccin
serotyp
sweden
split
market
aim
address
potenti
effect
incid
inpati
pneumonia
also
potenti
cost
save
among
vaccin
children
method
incid
per
quarter
inpati
pneumonia
case
identifi
region
among
children
year
region
implement
program
pneumococc
vaccin
start
region
switch
wherea
other
switch
result
among
children
year
follow
adjust
region
season
variat
proport
vaccin
per
quarter
incid
rate
ratio
irr
lower
children
vaccin
irr
ci
irr
ci
compar
vaccin
decreas
risk
observ
compar
irr
ci
addit
reduc
cost
per
person
year
conclus
decreas
risk
admiss
due
allcaus
pneumonia
observ
among
children
vaccin
pcv
strongli
pronounc
consequ
cost
save
larger
infant
vaccin
vaccin
conflict
interest
w
de
steenhuijsen
e
g
van
den
van
der
r
k
j
e
pediatr
immunolog
infecti
diseas
univers
medic
center
utrecht
utrecht
netherland
medic
microbiolog
immunolog
st
elisabeth
hospit
tilburg
netherland
institut
spaarn
hospit
hoofddorp
netherland
medic
microbiolog
center
infect
immun
amsterdam
academ
medic
center
amsterdam
netherland
medic
microbiolog
univers
medic
center
groningen
groningen
netherland
medic
microbiolog
univers
medic
center
utrecht
utrecht
netherland
background
elderli
lower
respiratori
tract
infect
major
caus
morbid
mortal
common
bacteri
pathogen
streptococcu
pneumonia
frequent
encount
upper
respiratori
tract
part
commens
flora
hypothes
dysbiosi
respiratori
microbiom
involv
pathogen
overgrowth
consequ
diseas
therefor
compar
oropharyng
microbiota
healthi
elderli
elderli
pneumonia
patient
method
determin
microbi
densiti
composit
oropharyng
sampl
elderli
year
pneumonia
patient
healthi
elderli
barcod
sequenc
region
gene
result
overal
bacteri
densiti
significantli
higher
pneumonia
patient
compar
control
median
vs
p
bacteri
divers
lower
pneumonia
patient
vs
speci
p
frequent
encount
genera
streptococcu
rothia
prevotella
veillonella
actinomyc
neisseria
lactobacillu
microbiota
profil
differ
healthi
elderli
elderli
pneumonia
patient
nonmetr
multidimension
scale
p
streptococcu
pseudo
pneumonia
vs
rothia
dentocariosa
vs
show
significantli
higher
abund
lactic
acid
bacteria
like
gemellal
vs
prevotella
melaninogenica
vs
anaerob
includ
veillonela
dispar
vs
show
significantli
decreas
abund
elderli
pneumonia
patient
compar
healthi
control
fdrcorrect
q
conclus
result
suggest
pneumonia
elderli
accompani
dysbiosi
bacteri
overgrowth
oropharyng
microbiom
whether
imbal
either
caus
factor
pathogenesi
pneumonia
epiphenomenon
yet
determin
conflict
interest
j
v
j
commun
health
christian
medic
colleg
vellor
india
microbiolog
christian
medic
colleg
vellor
india
christian
medic
colleg
recruit
birth
cohort
follow
babi
year
age
studi
incid
pneumonia
mening
age
group
studi
collect
data
pneumonia
mening
includ
streptococcu
pneumonia
method
babi
cohort
refer
base
hospit
suspect
pneumonia
mening
definit
sever
pneumonia
mening
per
guidelin
result
enrol
lost
follow
cohort
babi
cyo
child
year
observ
cyo
cohort
admit
pneumonia
pneumonia
rate
month
age
cyo
month
cyo
cyo
month
radiograph
confirm
pneumonia
rate
cyo
cyo
respect
xray
readabl
qualiti
lumbar
punctur
lp
rate
vellor
cyo
total
csf
done
infant
cell
count
mm
cellscu
mm
hib
cultur
posit
pneumonia
cohort
babi
lumbar
punctur
extrapol
cohort
incid
hospit
pneumonia
child
per
cyo
incid
mening
csf
tc
child
year
cyo
carriag
studi
nasopharyng
swab
taken
healthi
children
age
group
posit
pneumococcu
conclus
data
show
invas
pneumococc
diseas
present
age
group
month
conflict
interest
n
j
r
infecti
diseas
unit
soroka
univers
medic
center
bengurion
univers
negev
beersheva
israel
radiolog
hadassah
univers
medic
center
jerusalem
israel
background
aim
introduc
isra
vaccin
schedul
juli
gradual
replac
sinc
novemb
aim
determin
whether
hospit
visit
radiologicallyproven
communityacquir
alveolar
pneumonia
caap
among
children
reduc
pcv
introduct
method
ongo
prospect
populationbas
studi
initi
includ
hospit
visit
emergencyroom
hospit
radiographicallydiagnos
caap
center
medic
center
region
enabl
incid
calcul
defin
period
accord
vaccin
histori
prepcv
children
receiv
dose
children
receiv
dose
vaccin
impact
calcul
incid
rate
ratio
irr
adjust
ethnic
group
hospit
result
caap
case
enrol
annual
incid
declin
period
respect
figur
signific
reduct
observ
agegroup
especi
introduct
tabl
conclus
signific
declin
hospit
caap
visit
children
observ
introduct
signific
substanti
addit
reduct
introduct
conflict
interest
cg
rg
r
e
c
l
cg
mr
km
wh
polici
vanderbilt
univers
nashvil
usa
northwestern
univers
chicago
usa
vanderbilt
univers
nashvil
usa
vanderbilt
univers
nashvil
usa
rush
univers
chicago
usa
john
h
stroger
jr
hospit
chicago
usa
medicin
emori
univers
atlanta
usa
northwestern
univers
chicago
usa
center
immun
respiratori
diseas
cdc
atlanta
usa
medicin
vanderbilt
univers
nashvil
usa
background
whether
recommend
adult
unclear
assess
distribut
pneumococc
serotyp
use
pfizer
serotypespecif
urinari
antigen
detect
assay
uad
among
adult
enrol
center
immun
respiratori
diseas
cdc
etiolog
pneumonia
commun
epic
studi
initi
infant
vaccin
method
adult
year
hospit
communityacquir
pneumonia
enrol
januari
includ
infect
due
serotyp
detect
use
uad
compar
serotyp
distribut
consecut
respiratori
season
adult
adult
live
young
children
chronic
comorbid
result
among
adult
uad
result
enrol
median
age
year
iqr
overal
serotyp
detect
adult
includ
serotyp
common
serotyp
twenti
adult
serotyp
detect
fifteen
includ
serotyp
number
pneumonia
case
drop
consecut
season
declin
proport
caus
serotyp
signific
among
adult
live
children
tabl
conclus
pneumococc
detect
use
uad
due
serotyp
cover
chang
consecut
season
suggest
reduct
pneumonia
may
occur
among
adult
due
herd
effect
conflict
interest
av
p
j
mi
jc
b
g
intern
health
school
medicin
univers
otago
dunedin
nz
dunedin
new
zealand
medic
research
council
gambia
unit
fajara
gambia
control
elimin
theme
medic
research
council
gambia
unit
fajara
gambia
surviv
theme
medic
research
council
gambia
unit
fajara
gambia
infecti
tropic
diseas
london
school
hygien
tropic
medicin
london
unit
kingdom
background
aim
determin
risk
mortal
follow
discharg
hospit
gambian
children
suspect
pneumonia
sepsi
mening
method
children
resid
bass
health
demograph
surveil
system
bhdss
age
month
diagnos
suspect
pneumonia
sepsi
mening
admit
bass
health
centr
may
april
discharg
aliv
children
follow
day
discharg
vital
statu
monitor
bhdss
multivari
model
describ
mortal
associ
clinic
syndrom
admiss
b
predischarg
risk
factor
result
children
elig
analysi
die
followup
half
within
first
day
mortal
associ
posit
neg
age
hazard
ratio
hr
ci
everi
month
increas
pneumonia
sever
malnutrit
hr
ci
mening
sever
malnutrit
hr
ci
sepsi
sever
malnutrit
hr
ci
risk
factor
mortal
neck
stiff
hr
ci
midupp
arm
circumfer
hr
sever
malnutrit
hr
ci
nonmed
discharg
hr
ci
dri
season
hr
ci
oxygen
satur
hr
ci
per
percent
increas
haemoglobin
concentr
hr
cl
per
gdl
increas
temperatur
hr
per
increas
conclus
postdischarg
mortal
signific
rural
gambia
associ
particularli
malnutrit
children
high
risk
postdischarg
mortal
follow
care
conflict
interest
allianc
surveil
invas
pneumococci
asip
studi
gd
kl
unit
infecti
diseas
christian
medic
colleg
vellor
india
vaccin
access
center
john
hopkin
bloomberg
school
public
health
baltimor
usa
background
aim
inform
serotyp
caus
ipd
among
children
india
limit
aim
determin
serotyp
preval
syndrom
distribut
antimicrobi
suscept
pattern
ipd
case
among
children
year
across
multipl
geograph
site
india
method
allianc
surveil
invas
pneumoccoci
asip
network
januari
includ
state
tertiari
care
centersteach
institut
laboratori
sentinel
pediatrician
central
laboratori
particip
network
identifi
ipd
case
prospect
enrol
clinic
suspect
ipd
case
prospect
retrospect
laboratori
surveil
ipd
isol
children
year
clinic
symptom
suggest
pneumonia
mening
bacteremia
blood
cerebrospin
fluid
normal
steril
bodi
fluid
cultur
base
clinic
judgment
asip
recommend
pneumococc
isol
serotyp
quellung
method
antimicrobi
suscept
determin
result
ipd
case
identifi
prospect
lab
surveil
predomin
serotyp
penicillin
cefotaxim
nonsuscept
cotrimoxazol
erythromycin
resist
ipd
case
clinic
character
mening
pneumonia
anoth
syndrom
clinic
suspect
case
evalu
prospect
pneumococci
isol
mortal
overal
among
ipd
case
conclus
ipd
surveil
across
india
found
ipd
isol
includ
current
licens
avail
pcv
key
baselin
data
monitor
postintroduct
impact
pcv
introduc
indian
epi
conflict
interest
k
h
l
g
e
h
infecti
diseas
karolinska
univers
hospit
stockholm
sweden
infecti
diseas
karlstad
hospit
karlstad
sweden
infecti
diseas
eskilstuna
hospit
eskilstuna
sweden
infecti
diseas
falun
hospit
falun
sweden
environment
medicin
karolinska
institut
stockholm
sweden
infecti
diseas
univers
hospit
sweden
background
aim
optim
durat
antibiot
treatment
communityacquir
pneumonia
cap
spars
studi
open
random
control
studi
aim
compar
beta
lactam
treatment
fever
h
least
short
cours
therapi
standard
therapi
method
prospect
multicentr
studi
swedish
infecti
diseas
depart
patient
radiolog
confirm
uncompl
febril
cap
randomis
receiv
short
cours
therapi
standard
therapi
studi
regist
statist
equival
accept
cure
rate
differ
includ
confid
interv
ci
result
enrol
patient
advers
event
note
patient
standard
therapi
diarrhoea
oral
candida
infect
per
protocol
analysi
includ
patient
short
cours
therapi
patient
standard
therapi
clinic
cure
note
short
cours
therapi
standard
therapi
yield
advantag
standard
therapi
includ
ci
howev
among
patient
pneumococc
aetiolog
high
similar
rate
clinic
cure
note
short
cours
therapi
standard
therapi
conclus
present
studi
statist
equival
short
cours
therapi
standard
therapi
cap
cure
could
found
howev
patient
pneumococc
aetiolog
high
cure
rate
short
cours
therapi
note
support
use
short
cours
beta
lactam
therapi
patient
pneumococc
pneumonia
encourag
effort
detect
pneumococc
aetiolog
cap
conflict
interest
h
ms
k
ts
e
bm
je
bd
jc
agenc
de
ouagadoug
burkina
faso
provincial
de
la
de
ministri
health
togo
dapaong
togo
hospit
laboratori
ministri
health
togo
dapaong
togo
divis
ministri
health
togo
togo
regional
de
la
de
savan
ministri
health
togo
dapaong
togo
institut
pasteur
dakar
seneg
expertis
agenc
de
pari
franc
ecol
de
haut
etud
en
publiqu
pari
franc
agenc
de
pari
franc
background
aim
aim
document
burden
characterist
pneumococc
pneumonia
african
mening
belt
method
may
april
enrol
patient
admit
clinic
pneumonia
five
hospit
tone
district
northern
togo
obtain
blood
cultur
realtim
lyta
pcr
chest
xray
cxr
read
accord
standard
methodolog
identifi
patient
lobar
consolid
pleural
effus
result
among
patient
median
age
year
sever
pneumonia
posit
cxr
clinic
sever
cxrconfirm
pneumonia
rate
per
highest
among
person
year
age
annual
peak
incid
occur
dri
season
person
age
children
sever
cxrconfirm
pneumonia
rate
decreas
studi
period
diseas
season
less
evid
bacterem
pneumococc
pneumonia
account
case
cultur
yield
increas
age
addit
cultureneg
case
lytaposit
test
ongo
serotyp
account
isol
pcrposit
case
serotyp
ongo
serotyp
common
repres
case
respect
conclus
studi
first
document
burden
characterist
pneumococc
pneumonia
african
mening
belt
show
high
incid
across
age
group
season
similar
mening
among
adult
excel
coverag
impact
studi
plan
conflict
interest
ag
j
mra
cm
scienc
phd
program
ppgc
feder
univers
bahia
school
medicin
salvador
brazil
de
pesquisa
muniz
oswaldo
cruz
salvador
brazil
paulo
univers
school
public
health
sao
paulo
brazil
background
aim
communityacquir
pneumonia
cap
main
caus
death
children
year
worldwid
streptococcu
pneumonia
commonest
bacteri
agent
howev
difficult
identifi
pneumococc
cap
aim
evalu
associ
cytokin
admiss
pneumococc
cap
method
prospect
studi
conduct
emerg
room
feder
univers
bahia
hospit
salvador
brazil
children
age
year
admit
cap
evalu
admiss
clinic
radiolog
data
collect
well
biolog
sampl
investig
etiolog
agent
determin
serum
cytokin
dosag
rant
result
enrol
patient
boy
mean
age
month
pneumococc
infect
detect
case
among
median
concentr
pgml
interquartil
caus
agent
haemophilu
influenza
moraxella
catarrhali
atyp
bacteria
virus
mix
detect
case
median
concentr
pgml
interquartil
rang
pgml
area
roc
curv
predict
pnemococc
cap
p
multivari
analys
pneumococc
cap
depend
variabl
independ
predictor
pneumococc
infect
p
cutoff
point
pgml
conclus
independ
predictor
pneumococc
cap
conflict
interest
va
technolog
microbiolog
feder
polytechn
adoek
nigeria
incid
streptococcu
pneumonia
isol
pediatr
admit
variou
hospit
ekiti
ondo
state
month
januari
juli
investig
observ
sampl
collect
children
state
posit
isol
neg
indic
low
incid
state
higher
ondo
state
posit
sampl
isol
sputum
urin
blood
ear
swab
highest
number
posit
isol
male
femal
sputum
suscept
ciprofloxacin
loxacillin
urin
isol
suscept
ofloxacin
isol
blood
sampl
suscept
ciprofloxacin
gentamicin
isol
ear
swab
suscept
erythromycin
ciprofloxacin
suscept
ofloxacin
clindamycin
gentamicin
cotrimoxazol
ampicilin
cloxacillin
isol
urin
sampl
show
resist
major
antibiot
isol
blood
show
resist
antibiot
test
except
ciprofloxacin
gentamicin
two
isol
ear
swab
show
resist
ceftriaxon
augmentin
activ
antibiot
test
ciprofloxacin
gentamycin
erythromycin
ofloxacin
clindamycin
conflict
interest
p
p
prome
kielc
poland
institut
hygien
nation
institut
public
health
warsaw
poland
paediatr
gastroenterolog
nutrit
medic
univers
warsaw
warsaw
poland
background
aim
citi
kielc
poland
introduc
sinc
mandatori
vaccin
programm
children
year
age
aim
studi
analys
direct
indirect
effect
vaccin
pneumonia
incid
rate
followup
period
comparison
citi
ostrowiec
swietokrzyski
mandatori
vaccin
scheme
present
method
vaccin
given
scheme
complianc
rate
vaccin
reach
approx
follow
age
group
analys
year
period
cochranarmitag
test
investig
signific
trend
pneumonia
morbid
signific
deviat
test
import
trend
case
deviat
linear
confirm
mantel
test
result
greatest
decreas
pneumonia
morbid
analys
period
observ
children
year
age
age
group
declin
diagnos
pneumonia
follow
lower
also
statist
signific
declin
age
group
decreas
trend
continu
seven
consecut
year
observ
demonstr
also
statist
significantli
higher
rate
pneumonia
incid
among
age
group
citi
ostrowiec
swietokrzyski
conduct
mass
pneumococc
vaccin
program
conclus
result
clearli
prove
statist
signific
direct
indirect
effect
pneumonia
prevent
due
mass
vaccin
programm
conflict
interest
f
de
v
r
r
p
l
r
p
p
p
g
health
scienc
dissal
irccsaou
san
martinolstituto
nazional
per
la
ricerca
sul
cancro
genoa
itali
health
scienc
dissal
univers
genoa
genoa
itali
maritim
health
air
border
usmaf
ministri
health
genoa
itali
health
social
servic
prevent
public
health
vulner
social
group
liguria
region
genoa
itali
health
unit
asl
genoves
genoa
itali
region
agenc
ar
liguria
liguria
region
genoa
itali
pneumococc
studi
group
liguria
region
genoa
itali
background
aim
liguria
administr
region
northern
itali
character
decad
high
pcv
coverag
paediatr
age
group
new
recommend
free
activ
immunis
adult
risk
factor
subject
age
year
old
issu
main
aim
studi
descript
epidemiolog
clinic
burden
lower
respiratori
tract
infect
lrti
adult
year
age
ii
crossov
evalu
effect
introduct
increas
implement
vaccin
adult
age
year
old
term
emerg
depart
ed
access
lrti
obtain
syndrom
surveil
system
sss
method
popul
cohort
individu
age
year
old
activ
survey
month
ed
access
chief
complaint
base
sss
design
detect
analysi
ed
access
lrti
result
prepcv
period
annual
cumul
incid
ed
access
lrti
equal
year
adult
respect
year
adult
subject
identifi
sss
least
one
risk
condit
peak
year
cohort
new
ligurian
recommend
potenti
reach
ed
access
lrti
conclus
data
highlight
heavi
impact
lrti
term
ed
access
especi
elderli
subject
chronic
condit
use
sss
tool
monitor
pcv
vaccin
effect
conflict
interest
ao
b
g
p
mi
gv
em
ml
ki
gj
ei
cj
immunolog
south
texa
research
facilityth
univers
texa
health
scienc
center
san
antonio
san
antonio
usa
diseas
st
jude
children
research
hospit
memphi
usa
medicin
univers
milan
bicocca
monza
itali
veteran
health
care
system
univers
texa
health
scienc
center
san
antonio
san
antonio
usa
univers
alabama
birmingham
birmingham
usa
medicin
univers
texa
southwestern
medic
center
dalla
usa
biophys
univers
mississippi
medic
center
jackson
usa
anim
resourc
univers
texa
health
scienc
center
san
antonio
san
antonio
usa
section
pulmonarycrit
care
medicin
louisiana
state
univers
health
scienc
center
new
orlean
usa
individu
hospit
invas
pneumococc
diseas
ipd
frequent
experi
advers
cardiac
event
herein
describ
previous
unrecogn
cardiac
microles
form
within
myocardium
experiment
streptococcu
pneumonia
infect
mice
rhesu
macaqu
mice
microles
format
posit
correl
bacteri
burden
blood
serum
level
troponin
marker
cardiac
damag
microles
accompani
progress
chang
cardiac
electrophysiolog
measur
limblead
ecg
indic
develop
aberr
contractil
microles
increas
number
size
ipd
confin
heart
lack
infiltr
immun
cell
bacteri
transloc
across
cardiac
vasculatur
heart
tissu
requir
pneumococc
adhesin
cbpa
hostligand
laminin
receptor
platelet
activ
factor
receptor
myocardium
pneumococci
remain
extracellular
pore
form
toxin
pneumolysin
present
site
cell
death
determin
requir
microles
format
immun
fusion
construct
cbpa
peptid
pneumolysin
toxoid
protect
microles
format
conclud
cardiac
microles
form
ipd
contribut
toward
aberr
cardiac
electrophysiolog
microles
also
observ
nonhuman
primat
help
explain
high
incid
advers
cardiac
event
seen
human
ipd
conflict
interest
k
c
global
child
health
hospit
sick
children
toronto
canada
john
hopkin
bloomberg
school
public
health
toronto
canada
introduct
pneumonia
lead
killer
children
five
worldwid
caus
million
death
pneumonia
death
highli
concentr
asia
africa
death
pneumonia
decreas
sinc
reduct
like
possibl
part
diarrhoea
pneumonia
evid
synthesi
project
systemat
review
risk
factor
diarrhoea
pneumonia
south
east
asia
india
pakistan
nepal
sri
lanka
bangladesh
method
embas
medlin
ame
eastern
mediterranean
southeast
asian
databas
search
titl
abstract
articl
review
duplic
includ
paper
analysi
risk
factor
incid
sever
durat
diarrhoea
pneumonia
result
conclus
signific
differ
pneumonia
incid
child
age
gender
children
malnourish
increas
risk
pneumonia
pneumonia
mortal
rr
ci
rr
ci
respect
incomplet
immun
associ
increas
pneumonia
incid
rr
ci
children
live
crowd
household
higher
pneumonia
incid
rr
differ
pneumonia
mortal
sever
use
nonclean
fuel
sourc
significantli
increas
pneumonia
incid
rr
ci
breastfeed
significantli
protect
pneumonia
reduc
incid
higher
matern
patern
educ
associ
lower
pneumonia
incid
rr
ci
rr
respect
socioeconom
statu
signific
risk
factor
pneumonia
incid
importantli
vari
criteria
use
defin
pneumonia
studi
significantli
influenc
associ
estim
metaanalysi
conflict
interest
n
j
b
j
medicin
institut
child
health
kolkata
india
medicin
midnapor
medic
colleg
midnapor
india
medic
scienc
technolog
iitkharagpur
kharagpur
india
institut
child
health
kolkata
india
microbiolog
bell
vue
clinic
kolkata
india
background
aim
streptococcu
pneumonia
constitut
one
main
caus
sepsi
bacteremia
mening
pneumonia
infant
small
children
studi
aim
determin
preval
invas
diseas
due
pneumonia
along
serotyp
distribut
eastern
india
method
juli
august
children
year
enrol
across
centr
eastern
india
present
pneumonia
bacteremia
mening
blood
cultur
sampl
collect
written
inform
consent
parent
cultur
posit
pneumococcu
serotyp
antimicrobi
resist
determin
result
subject
cultur
posit
except
one
neissema
meningitidi
pneumonia
bacteremia
commonest
present
amongst
cultur
posit
case
nearli
follow
pneumonia
mening
serotyp
identifi
common
type
prevail
centr
rest
uncommon
like
common
serotyp
present
bacteremia
nephrot
syndrom
case
serotyp
isol
resist
cotrimoxazol
case
erythromycin
none
subject
vaccin
cultur
posit
subject
antibiot
naiv
subject
recov
hospit
stay
conclus
studi
show
pneumococcu
commonest
bacteria
isol
studi
popul
bacteremia
common
present
featur
epidemiolog
surveil
system
need
improv
get
better
yield
acknowledg
dr
anand
manoharan
asip
team
conflict
interest
p
e
mg
diseas
hospit
municip
chivilcoy
bueno
air
argentina
medicin
hospit
velez
sarsfield
bueno
air
argentina
bueno
air
argentina
bueno
air
argentina
background
aim
streptococcu
pneumonia
infect
associ
high
rate
morbid
mortal
certain
highrisk
group
includ
adult
year
studi
aim
evalu
compar
attitud
knowledg
cardiologist
car
internist
int
physician
pneumococc
vaccin
pv
well
recommend
administr
practic
perceiv
barrier
vaccin
deliveri
method
questionnair
avail
view
onlin
administ
email
physician
assess
pv
practic
attitud
measur
proport
test
result
respond
includ
studi
total
respons
rate
int
car
nineti
seven
percent
car
age
year
compar
int
p
respond
car
int
p
usual
administ
pv
least
patient
respond
commonli
indic
pv
person
chronic
respiratori
diseas
car
int
p
chronic
cardiovascular
diseas
car
int
p
inmmunosupres
condit
car
int
p
howev
proport
respond
usual
prescrib
pv
often
significantli
lower
car
vs
int
p
among
car
int
potenti
barrier
report
pv
includ
vaccin
cost
vs
p
patient
concern
vaccin
safeti
vs
p
inadequ
reimburs
vs
p
conclus
low
percentag
car
int
recommend
pv
patient
without
signific
differ
relat
attitud
knowledg
respond
usual
attend
patient
risk
factor
por
pneumococc
diseas
commit
specialist
pv
crucial
conflict
interest
mg
latin
american
antibiot
use
intens
care
unit
diseas
hospit
municip
chivilcoy
bueno
air
argentina
pfizer
bueno
air
argentina
argentina
background
aim
hospit
patient
intens
care
unit
icu
frequent
risk
subsequ
pneumococc
diseas
pd
despit
risk
often
vaccin
set
studi
assess
characterist
patient
icu
relat
candidaci
pneumococc
vaccin
pv
method
observ
crosssect
studi
latin
america
la
icu
complet
webbas
data
collect
form
data
hospit
adult
patient
oneday
point
preval
studi
main
outcom
measur
document
chart
review
risk
factor
rf
pd
communityacquir
pneumonia
cap
pv
statu
result
patient
indic
pneumococc
vaccin
accord
center
diseas
control
advisori
committe
immun
practic
acip
recommend
despit
patient
immun
statu
document
mean
number
rf
pd
ci
major
patient
age
chronic
heart
lung
diseas
respect
diabet
high
risk
condit
pd
observ
patient
sixtythre
patient
admit
icu
due
cap
among
patient
rate
pv
mean
rf
ci
p
conclus
patient
admit
la
icu
multipl
indic
pv
howev
small
percentag
receiv
vaccin
previou
hospit
admiss
hospit
provid
opportun
vaccin
patient
high
risk
develop
seriou
pd
complic
elig
screen
administr
pv
prior
discharg
qualifi
icu
patient
may
improv
immun
rate
conflict
interest
z
g
f
r
p
de
research
unit
quebec
univers
hospit
research
centr
quebec
citi
canada
quebec
univers
hospit
research
centr
quebec
citi
canada
quebec
nation
public
health
institut
quebec
citi
canada
prevent
medicin
laval
quebec
citi
canada
background
quebec
canada
pneumococc
conjug
vaccin
pcv
program
implement
decemb
first
use
replac
june
begin
vaccin
uptak
high
children
receiv
recommend
number
dose
aim
assess
rel
impact
two
vaccin
hospit
lower
respiratori
tract
infect
ltri
method
studi
popul
includ
children
born
observ
second
year
anniversari
hospit
record
main
diagnosi
ltri
identifi
provinci
administr
databas
medecho
monthli
birth
number
provid
quebec
statist
institut
birth
cohort
classifi
accord
main
vaccin
use
dose
cumul
hospit
frequenc
chf
month
age
comput
multivari
poisson
model
adjust
age
month
birth
viru
circul
ambient
temperatur
use
assess
vaccin
program
effect
first
hospit
result
analysi
includ
hospit
ltri
among
children
complet
followup
chf
among
children
expos
expos
p
multivari
analys
show
statist
signific
effect
age
month
birth
ambient
temperatur
respiratori
syncyti
viru
rsv
influenza
metapneumoviru
circul
differ
vaccin
conclus
result
ecolog
studi
interpret
care
abl
demonstr
substanti
differ
hospit
ltri
conflict
interest
c
r
r
pfizer
collegevil
usa
pfizer
den
hagu
netherland
background
pneumococc
conjug
vaccin
consist
demonstr
reduct
allcaus
pneumonia
across
countri
compar
method
result
real
world
pneumonia
effect
studi
pcv
immun
program
method
identifi
real
world
data
effect
pediatr
pcv
immun
program
allcaus
pneumonia
search
pubm
articl
publish
januari
septemb
search
term
includ
pneumonia
incid
increas
decreas
reduct
pcv
data
extract
includ
countri
data
sourc
vaccin
schedul
age
group
pre
post
period
pneumonia
definit
vaccin
effect
articl
report
multipl
region
separ
analyz
estim
report
author
percent
chang
incid
specifi
result
titl
articl
report
region
analys
identifi
among
articl
report
hospit
estim
report
outpati
estim
case
identifi
code
n
chart
review
n
appli
chest
radiograph
criteria
effect
report
articl
median
estim
children
year
n
children
year
n
iqr
children
year
n
studi
examin
region
children
month
median
reduct
iqr
conclus
consist
show
signific
allcaus
pneumonia
effect
vaccin
age
group
studi
design
vari
pneumonia
definit
prepostperiod
durat
research
cautious
compar
across
pneumonia
effect
studi
conflict
interest
perch
studi
vaccin
access
center
john
hopkin
school
public
health
baltimor
md
usa
background
limit
data
role
respiratori
viral
coinfect
among
children
microbiolog
confirm
pneumococc
pneumonia
mcpp
method
case
age
day
month
hospit
whodefin
severeveri
sever
pneumonia
age
frequencymatch
commun
control
africa
asia
site
induc
sputum
case
nasopharyng
swab
test
virus
fastrack
pcr
mcpp
defin
streptococcu
pneumonia
cultur
steril
specimen
lyta
pcr
lung
pleural
aspir
pneumococc
colon
defin
lyta
nasopharynx
compar
preval
virus
nasopharynx
mcpp
nonmcpp
case
african
site
mcpp
case
result
unadjust
preval
shown
figur
adjust
age
site
comparison
signific
seven
mcpp
case
pneumococcu
lung
aspir
two
virus
lung
coronaviru
cytomegaloviru
case
pneumococc
nasopharyng
colon
differ
mean
number
virus
among
colon
vs
colon
pneumococcu
vs
among
case
vs
among
control
conclus
mcpp
case
increas
frequenc
viral
coinfect
compar
nonmcpp
case
number
mcpp
case
limit
analys
relationship
pathogen
coinfect
nasopharynx
lung
need
studi
conflict
interest
k
ia
nv
p
jh
de
tuberculosi
instituto
de
biomedicina
caraca
venezuela
de
pediatria
hospit
de
jm
de
lo
rio
caraca
venezuela
tuberculosi
instituto
de
biomedicina
caraca
venezuela
background
communityacquir
pneumonia
cap
seriou
caus
morbid
among
children
develop
countri
hospit
cap
common
often
etiolog
agent
establish
estim
contribut
streptococcu
pneumonia
cap
children
method
total
children
year
old
cap
admit
hospit
de
jm
de
lo
rio
studi
prospect
june
march
test
pneumonia
includ
blood
cultur
blood
pcr
lyta
cpsa
urinari
pneumococc
antigen
detect
pleural
fluid
avail
cultur
pcr
addit
nasopharyng
swab
collect
bacteriolog
cultur
evalu
carriag
pneumonia
result
blood
cultur
neg
pneumonia
pcr
blood
posit
urin
antigen
test
posit
children
two
pleural
fluid
test
posit
pneumonia
cultur
andor
pcr
pneumonia
carriag
rate
frequent
serotyp
isol
children
posit
pneumonia
test
pcr
urin
antigen
carrier
cultur
posit
posit
test
result
conclus
addit
techniqu
increas
diagnosi
presumpt
pneumococc
etiolog
preliminari
result
studi
suggest
current
contribut
pneumonia
cap
much
higher
previous
report
util
standard
laboratori
techniqu
venezuela
conflict
interest
ew
un
u
h
e
ra
p
b
g
servic
depart
medic
research
council
gambia
unit
fajara
gambia
surveil
project
medic
research
council
gambia
unit
fajara
gambia
health
john
hopkin
bloomberg
school
public
health
baltimor
usa
intern
health
univers
otago
dunedin
new
zealand
diseas
control
london
school
hygien
tropic
medicin
london
unit
kingdom
background
aim
describ
aetiolog
pneumonia
among
patient
age
year
rural
area
gambia
method
conduct
prospect
pneumonia
surveil
may
august
six
health
facil
bass
health
demograph
surveil
system
eastern
gambia
introduc
august
may
patient
screen
nurs
referr
clinician
use
standard
criteria
diagnos
pneumonia
blood
cultur
collect
everi
patient
subset
patient
lung
pleural
aspir
collect
sampl
process
use
convent
method
result
month
surveil
specimen
collect
patient
suspect
pneumonia
age
posit
specimen
patient
blood
cultur
lung
aspir
one
pleural
aspir
patient
streptococcu
pneumonia
isol
serotyp
serotyp
total
serotyp
caus
organ
staphylococcu
aureu
salmonella
spp
casefat
rate
patient
age
patient
age
conclus
among
patient
age
year
suspect
pneumonia
pneumonia
predomin
organ
serotyp
account
pneumocc
isol
introduct
associ
herd
protect
older
age
group
potenti
reduct
pneumococc
pneumonia
adult
conflict
interest
perch
studi
vaccin
access
center
john
hopkin
bloomberg
school
public
health
baltimor
usa
background
creactiv
protein
crp
acutephas
reactant
associ
bacteri
infect
may
help
distinguish
pneumococc
pneumonia
method
pneumonia
etiolog
research
child
health
perch
studi
south
africa
blood
crp
level
whole
blood
lyta
test
case
age
day
month
hospit
whodefin
sever
sever
pneumonia
age
frequencymatch
commun
control
includ
upperrespiratori
tract
infect
blood
lyta
posit
nasopharyng
np
swab
induc
sputum
also
obtain
case
cultur
multiplexpcr
respiratori
pathogen
odd
ratio
proport
mgl
previous
establish
threshold
pneumococc
pneumonia
variou
pneumonia
outcom
calcul
result
case
pneumococcu
detect
pleural
fluid
blood
cultur
mgl
crp
associ
marker
pneumococc
bacterem
infect
figur
posit
associ
influenza
neg
associ
respiratori
syncyti
viru
associ
pneumonia
remain
adjust
pneumococc
allbacteri
infect
np
andor
conclus
elev
crp
suggest
bacteri
etiolog
children
whodefin
sever
sever
pneumonia
may
distinguish
pneumococcu
bacteri
pathogen
associ
viral
infect
crp
potenti
confound
low
sensit
blood
cultur
identifi
bacteri
infect
conflict
interest
kr
kg
j
medicin
bangalor
medic
colleg
victoria
hospit
bangalor
india
introduct
presenc
risk
factor
commun
acquir
pneumonia
cap
patient
play
import
role
diagnosi
manag
realli
challeng
treat
cap
patient
multipl
risk
factor
direct
impact
mortal
morbid
aim
studi
studi
risk
factor
profil
hospit
cap
patient
tertiari
hospitalto
studi
impact
risk
factor
treatment
outcom
case
materi
method
hospit
cap
patient
hospit
record
studi
analyz
variou
risk
factor
treatment
outcom
period
one
year
januari
decemb
risk
factor
profil
correl
variou
paramet
includ
recoveri
prolong
stay
hospit
unresolv
pneumonia
death
result
patient
male
femal
patient
belong
age
group
year
patient
risk
factor
patient
risk
factor
patient
risk
factor
commonest
risk
factor
smoke
alcohol
diabet
copd
hypertens
immunosuppress
advers
paramet
name
prolong
hospit
stay
unresolv
pneumonia
discharg
medic
advic
dama
death
note
patient
risk
factor
respect
conclus
risk
factor
identif
treatment
earliest
along
proper
manag
neumonia
decreas
mortal
morbid
hospit
cap
patient
conflict
interest
ks
cg
hj
medicin
hallym
univers
sacr
heart
hospit
anyang
korea
medicin
seoul
nation
univers
colleg
medicin
seoul
korea
access
depart
pfizer
pharmaceut
korea
ltd
seoul
korea
background
aim
communityacquir
pneumonia
cap
show
high
mortal
rate
despit
antibiot
treatment
suffici
data
diseas
burden
pneumonia
korea
studi
conduct
assess
diseas
burden
pneumonia
adult
accord
underli
diseas
type
age
group
method
perform
multicent
retrospect
observ
studi
collect
data
target
cap
patient
yr
hospit
data
assess
retrospect
review
patient
medic
record
diseas
burden
defin
measur
total
percapita
medic
fee
sever
hospit
length
stay
lo
mortal
medic
fee
calcul
multipli
total
use
medic
resourc
item
hospit
lo
medic
cost
unit
price
item
usd
korean
result
total
patient
includ
underli
diseas
total
percapita
medic
fee
highest
hospit
lo
longest
patient
chronic
renal
diseas
usd
day
patient
cn
disord
sever
level
curb
score
mortal
rate
highest
diseas
burden
higher
markedli
advanc
age
also
kind
underli
diseas
pneumonia
significantli
contribut
burden
diseas
conclus
korea
appropri
prevent
pneumonia
consid
effect
strategi
especi
patient
underli
diseas
older
age
group
conflict
interest
nj
p
r
mpe
e
depart
public
health
england
london
unit
kingdom
evalu
unit
public
health
england
manchest
unit
kingdom
vaccin
prevent
bacteria
depart
public
health
england
london
unit
kingdom
background
unit
kingdom
atrisk
children
age
year
recommend
pneumococc
polysaccharid
vaccin
addit
routin
pneumococc
conjug
vaccin
studi
describ
epidemiolog
serotyp
distribut
clinic
characterist
vaccin
statu
reason
nonvaccin
yearold
children
invas
pneumococc
diseas
ipd
method
public
health
england
conduct
enhanc
nation
surveil
ipd
england
wale
gener
practition
gp
contact
complet
questionnair
yearold
children
laboratoryconfirm
ipd
diagnos
two
epidemiolog
year
juli
result
ipd
episod
occur
children
incid
gp
case
complet
questionnair
comorbid
report
third
immunocompromis
chronic
respiratori
diseas
comorbid
pneumonia
common
present
ipdrel
casefat
children
comorbid
receiv
develop
associ
prior
vaccin
aor
ci
p
even
analysi
restrict
extra
serotyp
contain
pneumococc
conjug
vaccin
aor
ci
p
gp
elig
unvaccin
case
comorbid
mostli
unawar
child
requir
andor
expect
paediatrician
inform
administ
vaccin
conclus
quarter
children
comorbid
develop
ipd
receiv
prior
infect
among
children
comorbid
howev
evid
protect
serotyp
conflict
interest
g
e
h
h
e
depart
centro
de
estudio
funcei
ciudad
de
bueno
air
argentina
depart
hospit
f
lima
gener
roca
negro
argentina
hospit
maciel
montevideo
uruguay
depart
sanatorio
casmer
rivera
uruguay
sanatorio
casmer
rivera
uruguay
care
unit
hospit
region
de
instituto
de
social
paraguay
depart
centro
la
costa
servicio
migon
paraguay
background
communityacquir
pneumonia
cap
one
lead
caus
death
incid
cap
latinamerica
unknown
method
subject
resid
roca
citi
argentina
rivera
citi
uruguay
concepcion
citi
paraguay
diagnos
radiolog
confirm
cap
includ
incid
rate
defin
number
case
cap
popul
older
year
resid
surveil
area
divid
total
popul
risk
result
januari
august
subject
assess
diagnos
cap
global
incid
roca
per
popul
rivera
ci
ci
ci
ci
respect
mean
age
year
femal
episod
hospit
durat
stay
ds
day
ds
loss
activ
associ
cap
day
ds
mortal
rate
patient
subject
ever
receiv
pneumococc
vaccin
mortal
vaccin
subject
never
vaccin
p
mortal
subject
posit
urinari
antigen
pneumonia
vs
subject
neg
result
p
conclus
incid
adult
particularli
substanti
mortal
capepisod
posit
urinari
antigen
significantli
higher
pneumococc
vaccin
associ
lower
mortal
conflict
interest
sa
mj
h
c
c
e
c
respiratori
mening
diseas
nation
institut
communic
diseas
sandringham
johannesburg
south
africa
respiratori
mening
pathogen
research
unit
univers
witwatersrand
bertsham
johannesburg
south
africa
cross
hospit
paediatr
univers
cape
town
cape
town
south
africa
depart
ngwelezan
hospit
richard
bay
south
africa
diseas
branch
center
diseas
control
prevent
atlanta
usa
south
africa
diseas
branch
center
diseas
control
prevent
atlanta
usa
south
africa
background
pcv
introduc
south
africa
april
use
schedul
dose
age
week
supersed
pcv
may
evalu
pcv
effect
hospit
pbp
hivuninfect
children
method
match
casecontrol
studi
undertaken
three
site
april
juli
presum
bacteri
oneumonia
pbp
case
either
whodefin
radiographicallyconfirm
pneumonia
infiltr
chest
radiograph
creactiv
protein
mgl
hospit
control
hc
match
case
age
site
hivinfect
statu
agematch
commun
control
cc
identifi
birth
registri
enrol
soweto
cc
known
hivinfect
exclud
vaccin
effect
estim
adjust
ave
potenti
confound
result
hivuninfect
enrol
pbp
case
match
hc
n
pbp
case
soweto
cc
n
among
children
age
week
use
hc
ave
ageappropri
pcv
schedul
ci
overal
ci
soweto
among
children
week
use
hc
ave
ageappropri
pcv
ci
overal
ci
soweto
soweto
ave
use
cc
similar
observ
hc
ie
ci
ci
agegroup
week
week
respect
conclus
pcv
effect
pbp
studi
similar
efficaci
measur
random
control
trial
use
differ
vaccin
schedul
two
differ
control
type
hospit
commun
yield
similar
result
soweto
context
conflict
interest
h
h
k
diseas
surveil
center
nation
institut
infecti
diseas
tokyo
japan
school
medicin
tohoku
univers
sendai
japan
medicin
depart
saiseikai
yamagata
saisei
hospit
yamagata
japan
intern
medicin
saint
marianna
medic
school
kawasaki
japan
background
great
east
japan
earthquak
tsunami
march
devast
broad
area
age
popul
japan
follow
increas
incid
pneumonia
aim
evalu
health
impact
pneumonia
streptococcu
pneumonia
consid
opportun
prevent
avail
vaccin
method
retrospect
populationbas
survey
conduct
two
prefectur
miyagi
tsunami
affect
yamagata
control
key
hospit
two
prefectur
report
case
pneumococc
pneumonia
pp
invas
pneumococc
diseas
ipd
seen
two
year
novemb
octob
analysi
includ
patient
onset
date
locat
resid
result
distribut
regist
case
reveal
sharp
increas
pp
case
miyagi
immedi
disast
three
week
even
next
winter
miyagi
experienc
higher
incid
pp
collect
populationbas
incid
rate
per
person
year
entir
studi
period
statist
significantli
higher
miyagi
yamagata
p
case
pp
miyagi
like
resid
evacu
camp
conclus
natur
disast
increas
incid
pp
among
age
popul
possibl
reason
includ
depriv
regular
medic
nurs
care
high
densiti
popul
insuffici
live
suppli
evacu
shelter
psycholog
stress
weaken
immun
system
delay
recoveri
infrastructur
cold
climat
tohoku
might
even
worsen
pp
burden
senior
popul
follow
winter
conflict
interest
v
p
h
microbiolog
infecti
diseas
chacha
nehru
bal
chikitsalaya
new
delhi
india
pulimood
laboratori
infect
immun
inflamm
bmpliii
depart
medicin
unit
infecti
diseas
christian
medic
colleg
vellor
india
background
aim
develop
nation
almost
time
higher
diseas
burden
ipd
develop
world
present
studi
aim
determin
occurr
invas
pneumococc
diseas
children
studi
also
intend
determin
preval
serotyp
suscept
profil
streptococcu
pneumonia
india
method
present
studi
observ
prospect
hospit
base
studi
children
age
year
clinic
syndrom
includ
pneumonia
radiograph
evid
meet
clinic
criteria
clinic
suspect
mening
suggest
bacteri
mening
includ
blood
csf
andor
pleural
fluid
collect
cultur
bacteri
identif
suscept
test
perform
use
system
serotyp
perform
use
quellung
test
result
total
children
enrol
septemb
march
pneumonia
isol
children
cultur
posit
higher
children
pneumonia
effus
follow
mening
penicillin
resist
observ
use
mening
breakpoint
clsi
penicillin
resist
observ
use
pneumonia
breakpoint
case
fatal
studi
popul
cultur
posit
case
twenti
six
pneumococc
serotyp
implic
exist
vaccin
coverag
increas
vaccin
respect
use
india
specif
conjug
pneumococc
vaccin
conclus
ipd
signific
morbid
mortal
indian
set
penicillin
still
remain
choic
treatment
pneumococc
pneumonia
howev
mening
case
treat
high
dose
gener
cephalosporin
exist
pneumococc
vaccin
good
coverag
enhanc
use
india
specif
vaccin
conflict
interest
v
gd
kl
medicin
unit
infecti
diseas
christian
medic
colleg
hospit
vellor
india
microbiolog
chacha
nehru
bal
chikitsalya
delhi
india
vaccin
access
center
john
hopkin
bloomberg
school
public
health
baltimor
usa
background
pneumococc
diseas
data
among
indian
children
limit
character
children
year
hospit
suspect
ibd
cnbc
hospit
delhi
method
children
year
suspect
pneumococc
diseas
enrol
prospect
septemb
suspect
pneumonia
defin
cough
tachypnea
retract
respiratori
distress
breathless
chestxray
cxr
taken
suspect
mening
defin
fever
plu
physiciandiagnos
mening
sign
alter
conscious
cerebrospin
fluid
csf
collect
blood
csf
pleural
fluid
specimen
cultur
result
children
enrol
age
year
cxr
taken
retract
blood
pleural
fluid
collect
respect
suspect
mening
blood
csf
pleural
fluid
collect
respect
pneumococci
isol
blood
n
andor
csf
n
age
year
suspect
mening
abnorm
cxr
whodefin
alveolar
consolid
cxrac
haemophilu
influenza
isol
suspect
mening
abnorm
chestxray
cxrac
isol
blood
n
csf
n
pleural
fluid
n
staphylococcu
aureu
n
escherichia
coli
n
salmonella
typhi
n
also
isol
death
bacterium
isol
h
staphylococcu
coagulas
conclus
pneumococcu
common
pathogen
isol
children
hospit
suspect
ibd
delhi
hospit
isol
rate
similar
observ
elsewher
conflict
interest
r
p
nation
centr
immunis
research
surveil
westmead
australia
background
aim
program
commenc
australia
dose
month
age
associ
signific
reduct
hospitalis
pneumonia
first
year
program
updat
previou
studi
investig
impact
june
method
hospit
discharg
australia
primari
diagnosi
code
pneumonia
includ
juli
june
neg
binomi
regress
model
use
quantifi
impact
ratio
postvaccin
prevaccin
hospitalis
rate
adjust
season
prevaccin
background
trend
result
signific
decreas
year
postvaccin
seen
hospitalis
code
pneumococc
unspecifi
caus
increas
seen
specifi
caus
allcaus
pneumonia
signific
decreas
year
age
group
first
year
postvaccin
similar
addit
anoth
year
data
smaller
decreas
older
age
group
longer
signific
tabl
conclus
decreas
allcaus
pneumonia
hospitalis
associ
introduct
schedul
sustain
year
postvaccin
children
year
age
older
age
group
conflict
interest
j
b
r
e
n
perch
studi
surviv
medic
research
council
unit
gambia
fajara
gambia
hopkin
bloomberg
school
public
health
baltimor
usa
background
aim
streptococcu
pneumonia
carriag
among
without
pneumonia
provid
insight
evolv
epidemiolog
pneumococc
diseas
present
data
gambian
site
pneumonia
etiolog
research
child
health
perch
project
method
case
children
year
whodefin
sever
sever
pneumonia
healthi
control
commun
frequencymatch
age
season
nasopharyngealoropharyng
npop
swab
collect
particip
induc
sputum
collect
case
cultur
quantit
pcr
qpcr
perform
specimen
isol
serotyp
antibiot
suscept
test
perform
isol
result
carriag
rate
pneumonia
similar
case
control
npop
specimen
examin
cultur
qpcr
compar
previou
local
data
preval
pneumonia
cultur
lower
p
npop
specimen
compar
examin
qpcr
vaccin
coverag
npop
specimen
compar
p
prior
introduct
coverag
pneumococci
predomin
carriag
serotyp
isol
show
complet
intermedi
resist
penicillin
firstlin
drug
sever
pneumonia
set
isol
addit
resist
secondlin
drug
chloramphenicol
conclus
appear
influenc
serotyp
distribut
pneumonia
carriag
resist
pneumococci
standard
antibiot
seen
appreci
minor
conflict
interest
k
v
u
v
h
g
e
g
n
k
j
v
h
depart
pulmonari
medicin
univers
athen
chest
diseas
hospit
sotiria
athen
greec
clinic
univers
hospit
larissa
univers
thessali
larissa
greec
depart
pfizer
hella
athen
greec
depart
pulmonari
medicin
chest
diseas
hospit
sotiria
athen
greec
pulmonolog
clinic
gener
hospit
kavala
kavala
greec
depart
pulmonari
medicin
chest
diseas
hospit
sotiria
athen
greec
depart
amalia
fleme
gener
hospit
athen
greec
depart
pulmonari
medicin
chest
diseas
hospit
sotiria
athen
greec
pulmonari
depart
sismanoglio
gener
hospit
athen
greec
laboratori
chest
diseas
hospit
sotiria
athen
greec
medicin
depart
gener
hospit
kavala
kavala
greec
medicin
depart
evaggelismo
gener
hospit
athen
greec
microbiolog
univers
thessali
larissa
greec
laboratori
amalia
fleme
gener
hospit
athen
greec
depart
pulmonari
medicin
chest
diseas
hospit
sotiria
athen
greec
depart
intern
medicin
univers
athen
univers
gener
hospit
attikon
athen
greec
health
clinic
princeton
usa
depart
intern
medicin
hygeia
gener
hospit
athen
greec
background
streptococcu
pneumonia
remain
one
major
bacteri
caus
commun
acquir
pneumonia
cap
aim
describ
serotyp
distribut
adult
chest
xray
confirm
pneumococc
cap
pcap
greec
method
interim
analysi
data
prospect
observ
studi
conduct
adult
old
clinicali
radiographicali
confirm
cap
examin
emerg
depart
secondari
tertiari
hospit
present
confirm
pneumonia
made
detect
specif
antigen
urin
test
investig
serotyp
includ
pneumococc
conjug
vaccin
urin
antigen
detect
uad
assay
perform
luminex
platform
pfizer
central
lab
pearl
river
ny
usa
result
total
case
xray
confirm
cap
mean
age
year
record
examin
urin
specimen
reveal
case
posit
test
uad
posit
case
also
posit
test
addit
posit
case
neg
uad
test
among
pcap
case
detect
noncultur
method
caus
serotyp
includ
preval
serotyp
follow
conclus
major
pcap
case
studi
seem
attribut
serotyp
noncultur
method
specif
uad
test
may
provid
better
mean
detect
pcap
conflict
interest
j
van
uz
leuven
leuven
belgium
practic
research
link
linkebeek
belgium
diseas
chu
st
pierr
brussel
belgium
pfizer
brussel
belgium
background
aim
pneumococc
diseas
larg
underrecogn
gener
practic
aim
evalu
percentag
streptococcu
pneumonia
sever
lower
respiratori
tract
infect
slrti
primari
care
use
commerci
urinari
antigen
detect
test
evalu
profil
patient
clinic
sign
healthcar
use
loss
function
pneumococc
slrti
comparison
nonpneumococc
slrti
method
multicent
prospect
epidemiolog
studi
slrti
primari
care
patient
includ
base
clinic
sign
slrti
pneumococc
infect
identifi
urinari
antigen
detect
binaxnow
investig
blind
result
binaxnowposit
case
binaxnowneg
control
followedup
week
compar
result
patient
enrol
gener
practition
gp
februari
march
binaxnow
test
posit
patient
posit
case
neg
control
compar
posit
patient
women
p
less
exposur
young
children
p
patient
without
revenu
replac
revenu
p
less
season
influenza
vaccin
p
copd
p
clinic
sign
present
selfrat
health
lower
number
gp
visit
p
number
work
day
loss
p
number
assist
day
higher
p
conclus
current
avail
urinari
antigen
detect
method
identifi
pneumococc
infect
limit
number
lrti
patient
primari
care
patient
symptom
impair
requir
medic
care
studi
sponsor
pfizer
conflict
interest
dn
microbiolog
woodland
hospit
kolkata
india
communityacquir
pneumonia
cap
caus
sever
pathogen
streptococcu
pneumonia
one
caus
cap
older
adult
lead
seriou
life
threaten
secondari
multidrug
resist
gram
neg
infect
even
older
adult
old
male
patient
known
diabet
hypertens
chronic
obstruct
pulmonari
diseas
present
fever
confus
pleurit
chest
pain
respiratori
distress
cough
bloodting
expector
examin
tachypnoea
right
basal
crep
curb
score
admit
investig
treatment
xray
right
lower
pneumonia
total
leukocyt
count
tlc
neutrophil
creactiv
protein
crp
consid
case
cap
emper
antibiot
start
inj
gm
iv
three
time
daili
td
azithromycin
daili
collect
sputum
blood
cultur
patient
need
mechan
ventil
day
worsen
dyspnea
hypoxia
sputum
gram
stain
plenti
pu
cell
occasion
epitheli
cell
fair
number
gram
posit
encapsul
diplococci
like
pneumococci
culturemix
growth
pneumococc
pneumonia
like
treatment
continu
reonset
fever
day
tachypnea
hypoxia
reintub
increas
tlc
endotrach
et
secret
repeat
xray
found
new
opac
left
lower
lung
field
procalcitonin
crp
consid
case
ventilatorassoci
pneumonia
vap
antibiot
escal
done
meropenem
intraven
iv
td
collect
et
suction
blood
cultur
cultur
grew
acinetobact
baumannii
sensit
colistinpoli
b
colistin
ad
exist
regim
million
unit
mu
load
follow
td
accord
creatinin
clearanc
cosid
synergist
effect
patient
becam
afebril
within
next
hour
follow
success
wean
ventil
antibiot
therapi
continu
total
day
patient
success
discharg
day
complet
microbiolog
clearanc
life
threaten
organ
pathogen
may
also
help
resist
gram
neg
pathogen
establish
previous
infect
host
prevent
primari
infect
avoid
seriou
secondari
infect
older
adult
conflict
interest
ct
tn
tdh
eh
kt
dk
pharmaci
sungkyunkwan
univers
suwon
korea
clinic
laboratori
scienc
dongeui
univers
busan
korea
caseinolyt
proteas
l
clpl
member
chaperon
famili
found
mainli
gramposit
bacteria
infect
clpl
highli
express
refold
stressinduc
denatur
protein
least
import
adher
howev
mechan
clpl
modul
pneumococc
virul
poorli
understood
investig
clpl
inhibit
adher
streptococcu
pneumonia
human
lung
cell
use
microarray
western
blot
analys
clpl
found
induc
activ
small
gtpase
rho
decreas
ratio
cofilin
pcofilin
regul
actin
dynam
thu
actin
reorgan
cytoskeleton
rearrang
increas
clpl
mutant
infect
cell
compar
wild
type
infect
cell
filament
format
also
higher
infect
cell
wild
type
infect
cell
cell
show
impair
filament
format
decreas
pneumonia
adher
cell
result
demonstr
novel
role
clpl
pneumococc
resist
adher
host
cell
infect
provid
insight
understand
interact
host
pathogen
conflict
interest
ms
ja
j
j
k
k
r
f
jag
demographi
kemriwellcom
trust
research
programm
kilifi
kenya
diagnost
radiolog
aga
khan
univers
nairobi
nairobi
kenya
kemriwellcom
trust
research
programm
kilifi
kenya
radcliff
hospit
oxford
univers
hospit
nh
trust
oxford
unit
kingdom
hospit
oxford
univers
hospit
nh
trust
oxford
unit
kingdom
background
aim
radiologicallyconfirm
pneumonia
rcp
use
import
endpoint
pneumococc
vaccin
trial
report
radiograph
subject
individu
variat
agreement
statist
use
valid
studi
studi
aim
compar
three
measur
cohen
kappa
percent
agreement
method
team
clinician
radiologist
attend
threeday
train
cxr
interpret
rcp
use
standard
set
question
use
interpret
radiograph
chest
radiograph
children
whodefin
sever
sever
pneumonia
read
initi
two
reader
report
radiograph
independ
discord
result
concord
read
progress
second
level
arbitr
initi
read
repeat
subset
introduc
randomli
assess
intraobserv
variat
sensit
specif
test
first
level
reader
arbit
panel
read
consid
gold
standard
result
analyz
radiograph
sinc
incomplet
field
percent
agreement
kappa
rcp
rang
read
criteria
respect
level
one
reader
kappa
intraobserv
variabl
sensit
rang
specif
conclus
train
interpret
standard
agreement
two
reader
rel
high
repeat
moder
good
howev
upto
true
case
pneumonia
may
miss
normal
radiograph
misclassifi
pneumonia
conflict
interest
youth
action
tobacco
control
health
ibadan
nigeria
background
aim
consist
evid
children
expos
environment
tobacco
smoke
et
higher
incid
asthma
ear
throat
diseas
worsen
asthma
symptom
lung
symptom
cough
wheez
pneumonia
object
studi
consid
exposur
et
risk
factor
increas
respiratori
childhood
infect
pneumonia
south
west
region
nigeria
materi
method
descript
cross
section
studi
carri
state
ogun
lago
akur
oyo
ekiti
multistag
cluster
random
sampl
employ
select
respond
state
data
collect
use
structur
questionnair
train
interview
result
record
avail
analysi
male
femal
major
live
parent
live
mother
alon
live
rel
analysi
done
use
spss
version
preval
exposur
et
determin
preval
children
expos
et
southwest
region
nigeria
studi
reveal
children
region
respiratori
childhood
infect
expos
environment
tobacco
smoke
pneumonia
case
attribut
et
howev
parentsrel
see
problem
use
cigarett
tobacco
product
clearli
state
case
respiratori
childhood
infect
pneumonia
combin
attribut
et
south
west
region
nigeria
conclus
sinc
et
much
neg
effect
children
south
west
region
nigeria
effort
tailor
toward
protect
children
et
reduc
rate
children
expos
et
therebi
curb
reduc
respiratori
childhood
infect
pneumonia
nigeria
conflict
interest
mn
h
n
v
jn
f
b
g
infectiologi
charl
antananarivo
fondat
antananarivo
madagascar
antananarivo
et
enfant
tsaralalana
fondat
antananarivo
madagascar
pathogen
laboratori
fondat
lyon
franc
background
aim
first
site
pilot
multicentr
pneumonia
studi
gabriel
network
patient
enrol
launch
decemb
final
purpos
provid
inform
pneumonia
etiolog
virus
bacteri
improv
case
manag
pneumonia
ill
child
madagascar
method
hospitalbas
casecontrol
studi
carriedout
one
center
locat
antananarivo
less
year
need
enrol
case
control
year
age
respiratori
specimen
whole
blood
collect
pneumonia
case
nasal
swab
control
virus
bacteria
identifi
use
realtim
multiplex
pcr
assay
respiratori
fasttrack
diagnost
streptoccu
pneumonia
serotyp
posit
sampl
result
main
bacteri
agent
found
case
control
respiratori
sampl
pneumonia
respect
staphylococcu
aureu
haemophilu
influenza
b
mycoplasma
pneumonia
chlamydia
pneumonia
less
repres
viral
popul
respiratori
syncyti
viru
rsv
princip
agent
found
case
control
human
metapneumoviru
hmpv
influenzaab
found
mainli
case
rhinovirus
bocavirus
enterovirus
found
equal
control
case
main
pneumonia
serotyp
repres
less
proport
conclus
studi
allow
descript
etiolog
pneumonia
among
hospit
children
madagascar
result
permit
better
implement
target
cur
prevent
measur
conflict
interest
da
neve
j
de
microbiologia
faculdad
de
medicina
da
universidad
de
lisboa
lisbon
portug
background
aim
noninvas
pneumococc
pneumonia
nipp
frequent
caus
morbid
mortal
among
adult
aim
determin
serotyp
distribut
isol
caus
nipp
adult
herd
effect
childhood
vaccin
method
total
nipp
isol
collect
isolatesyear
chosen
randomli
serotyp
test
antimicrobi
resist
result
serotyp
divers
high
studi
year
simpson
index
divers
overal
common
serotyp
serotyp
consist
recov
nipp
throughout
studi
year
serotyp
strong
reduct
serotyp
includ
individu
serotyp
decreas
serotyp
increas
compar
serotyp
nipp
ipd
immedi
prior
avail
adult
serotyp
amongst
common
infect
potenti
coverag
ipd
nipp
erythromycin
resist
nipp
isol
increas
conclus
similarli
happen
adult
ipd
effect
adult
nipp
childhood
vaccin
serotyp
distribut
contemporari
nipp
ipd
isol
differ
conflict
interest
g
feroz
kl
kempegowda
institut
medic
scienc
bangalor
india
background
aim
countri
epidemiolog
data
invas
streptococcu
pneumonia
spars
limit
low
sensit
cultur
method
gold
standard
diagnos
invas
infect
inadequ
serotyp
data
pan
india
distribut
pneumomococc
serotyp
pidop
studi
network
design
identifi
characterist
invas
pneumococc
diseas
children
comb
cultur
method
molecular
techniqu
serotyp
isol
amass
across
center
method
hospit
base
prospect
observ
studi
conduct
hospit
india
kim
bangalor
dmc
ludhiana
umc
jodhpur
ich
chennai
children
year
age
present
clinic
suspect
ipd
pneumonia
initi
empir
antibiot
therapi
enrol
poi
point
interest
softwar
use
standard
collect
ecrf
real
time
laboratori
facil
rtpcr
detect
pneumonia
convent
molecular
serotyp
archiv
establish
central
research
laboratori
bangalor
result
septemb
octob
children
enrol
studi
four
particip
center
present
pneumonia
mening
cultur
posit
realtim
pcr
rtpcr
sampl
collect
kim
center
conclus
preliminari
data
suggest
approach
combin
cultur
techniqu
molecular
method
improv
identif
pneumococc
infect
children
prospect
studi
expect
provid
critic
data
pneumococc
infect
preval
serotyp
represent
indian
popul
support
public
health
polici
develop
india
conflict
interest
j
ruiz
mw
sa
wp
discoveri
develop
glaxosmithklin
vaccin
wavr
belgium
de
desarrollo
de
proyecto
avanzado
en
cedepap
argentina
sciencen
research
foundat
vaccin
prevent
diseas
medic
research
council
respiratori
mening
pathogen
research
unit
univers
witwatersrand
johannesburg
south
africa
background
aim
sever
doubleblind
random
control
trial
dbrct
pneumococc
conjug
vaccin
pcv
demonstr
similar
point
estim
vaccin
efficaci
rang
pneumonia
alveolar
consolid
follow
infant
immun
examin
durat
age
dbrct
method
review
dbrct
compar
perprotocol
efficaci
differ
pcv
follow
infant
immun
first
episod
communityacquir
pneumonia
alveolar
consolid
accap
use
standard
definit
avail
age
tabl
result
appear
maintain
third
year
life
gambia
soweto
phidcv
latin
america
tabl
contrast
wane
accap
observ
first
year
life
northern
california
kaiser
permanent
trial
bohol
trial
conclus
evid
phidcv
provid
extend
protect
accap
third
year
life
abil
pcv
maintain
efficaci
year
age
seem
correl
immunogen
serotyp
composit
suggest
trend
agedepend
declin
vaccin
might
due
factor
intersit
variat
pneumonia
etiolog
diseas
sever
careseek
pattern
fund
glaxosmithklin
biolog
sa
conflict
interest
f
shishu
hospit
depart
microbiolog
child
health
research
foundat
dhaka
bangladesh
center
global
health
ohio
usa
gynecolog
univers
siena
siena
itali
introduct
pneumonia
caus
substanti
child
mortal
morbid
absenc
pcv
bangladesh
studi
aim
estim
possibl
impact
pcv
pneumonia
diseas
burden
overal
mortal
among
children
age
month
follow
introduct
pcv
bangladesh
method
studi
estim
pcv
prevent
pneumonia
morbid
mortal
base
pneumonia
diseas
burden
bangladesh
pcv
effect
demonstr
countri
method
estim
pcv
prevent
clinic
pneumonia
case
hospit
death
overal
death
shown
sensit
analys
perform
use
avail
data
differ
approach
ascertain
uncertainti
rang
result
pcv
prevent
pneumonia
mortal
morbid
estim
studi
summar
conclus
introduct
pcv
would
great
public
health
impact
bangladesh
studi
requir
test
studi
result
introduct
pcv
countri
acknowledg
univers
siena
novarti
vaccin
academi
itali
samir
k
saha
conflict
interest
r
w
canadian
public
health
laboratori
microbiolog
laboratori
public
health
agenc
canada
winnipeg
canada
background
pneumococc
conjug
vaccin
introduc
canada
studi
present
distribut
serotyp
invas
streptococcu
pneumonia
canada
method
total
isol
pneumonia
steril
clinic
site
blood
n
cerebr
spinal
fluid
n
pleural
fluid
n
steril
site
n
serotyp
isol
aggreg
age
year
n
adult
year
n
senior
year
n
unknown
age
n
serotyp
determin
quellung
reaction
use
commerci
antisera
result
serotyp
preval
overal
togeth
account
isol
repres
n
isol
children
year
age
n
isol
adult
year
age
n
senior
year
age
serotyp
next
preval
serotyp
overal
n
total
isol
n
children
age
year
n
adult
age
n
senior
age
year
anoth
serotyp
also
preval
age
group
consist
n
isol
overal
n
isol
children
year
age
n
isol
adult
year
age
n
isol
senior
year
age
conclus
continu
surveil
pneumonia
import
recogn
replac
serotyp
assess
effect
reduc
invas
pneumococc
diseas
canada
conflict
interest
chen
x
x
bai
care
union
hospit
wuhan
china
tongji
medic
colleg
wuhan
china
care
chendu
medic
colleg
chengdu
china
care
reme
hospit
pekin
china
background
respiratori
tract
infect
common
intens
care
unit
icu
high
rate
mortal
aim
studi
identifi
incid
ventilatorassoci
pneumonia
vap
antibiot
suscept
shortterm
outcom
icu
method
studi
carri
period
month
five
icu
depart
chines
hospit
patient
respiratori
tract
infect
diagnos
first
day
icu
stay
sampl
respiratori
specimen
incid
rate
distribut
pathogen
calcul
logist
regress
analysi
perform
result
total
patient
develop
vap
common
microorgan
found
staphylococcu
aureu
steptococcu
pneumonia
pseudomona
aeroginosa
klebsiella
pneumonia
haemophilu
influenza
other
multidrug
resist
mdr
pathogen
found
vap
pneumonia
isol
mdr
inappropri
initi
antimicrobi
treatment
significantli
higher
patient
vap
greater
mortal
rate
longer
durat
icu
stay
p
mortal
among
vap
caus
pneumonia
conclus
vap
common
nosocomi
infect
icu
incid
rate
pneumonia
rapidli
go
mdr
serotyp
grow
progress
way
icu
vap
pneumonia
one
lead
caus
icu
mortal
staphylococcu
aureu
increas
preval
mdr
pathogen
earli
vap
indic
inappropri
use
antibiot
lead
caus
vap
main
predict
factor
mortal
icu
stay
much
greater
cost
icu
conflict
interest
pragna
hospit
hyderabad
india
background
aim
data
regard
age
specif
rate
diseas
distribut
organ
caus
pneumonia
children
limit
india
identif
etiolog
agent
particularli
difficult
pediatr
popul
studi
design
studi
etiolog
communityacquir
bacterem
pneumonia
children
method
hospit
base
prospect
studi
children
age
group
month
year
symptom
suggest
cough
cold
fever
temperatur
durat
day
enrol
children
histori
known
signific
congenit
acquir
diseas
clinic
diagnos
febril
ill
exclud
children
investig
blood
cultur
creactiv
protein
crp
complet
blood
count
cbc
chest
xray
result
major
age
group
month
year
follow
age
group
month
month
patient
show
blood
cultur
posit
major
age
group
month
wherea
least
age
group
month
commonli
isol
bacteria
staphylococcu
aureu
klebsiella
pneumonia
staphylococcu
spp
histori
exposur
smoker
famili
cultur
posit
among
patient
expos
passiv
smoke
blood
cultur
posit
conclus
preliminari
studi
result
document
common
bacteri
pathogen
caus
pneumonia
children
provid
evid
polici
maker
strengthen
child
health
program
india
conflict
interest
jc
jn
h
bm
k
ms
je
g
bd
ts
agenc
de
pari
franc
pathogen
laboratori
fondat
lyon
franc
agenc
de
ouagadoug
burkina
faso
expertis
agenc
de
pari
franc
hospit
laboratori
ministri
health
togo
dapaong
togo
provincial
de
la
de
ministri
health
togo
dapaong
togo
regional
de
la
de
savan
ministri
health
togo
dapaong
togo
ecol
de
haut
etud
en
publiqu
pari
franc
divis
ministri
health
togo
togo
background
aim
aim
describ
viral
bacteri
colon
among
pneumonia
patient
tone
district
northern
togo
method
august
juli
obtain
blood
cultur
realtim
multiplex
pcr
rtmpcr
bacteri
identif
nasal
aspir
bacteri
viral
test
rtmpcr
respiratori
fast
track
diagnost
chest
radiograph
assess
endpoint
pneumonia
lobar
consolid
pleural
effus
patient
admit
clinic
pneumonia
five
hospit
tone
district
pneumococc
serotyp
perform
quellung
rtmpcr
result
among
nasal
aspir
posit
bacteria
alon
virus
alon
common
virus
rhinoviru
influenza
b
hmpv
five
patient
rsv
pneumococcu
identifi
case
staphylococcu
aureu
haemophilu
influenza
type
b
children
like
colon
person
year
bacteria
vs
p
vs
pneumococcu
p
virus
vs
p
pneumococc
carriag
associ
endpoint
pneumonia
vs
p
vs
among
patient
blood
cultur
pcr
posit
pneumococcu
colon
concord
serotyp
blood
nasopharynx
conclus
sever
virus
bacteria
frequent
identifi
among
pneumonia
patient
data
healthi
control
need
determin
role
pathogen
etiolog
pneumonia
conflict
interest
f
p
lc
g
g
c
v
c
ircc
foundat
ca
granda
ospedal
maggior
policlinico
milan
itali
scienc
pediatr
section
depart
health
scienc
univers
florenc
anna
meyer
children
univers
hospit
florenc
itali
pictur
studi
singlecentr
observ
crosssect
prospect
studi
clinic
pattern
pneumococc
infect
patient
communityacquir
pneumonia
cap
primari
object
describ
proport
communityacquir
pneumonia
attribut
streptococcu
pneumonia
sp
hospit
cap
patient
secondari
object
describ
cap
attribut
sp
accord
sociodemograph
clinic
variabl
describ
clinic
evolut
cap
defin
proport
bacteriaem
non
bacteriaem
episod
hospit
admiss
describ
serotyp
distribut
antibiot
resist
pattern
pneumococc
isol
estim
inhospit
discharg
mortal
hospit
resourc
util
serotyp
distribut
antibiot
resist
pattern
pneumococc
isol
admiss
hospit
evalu
total
number
patient
male
mean
age
enrol
patient
die
hospit
patient
die
discharg
patient
untrac
discharg
withdrew
inform
consent
discharg
total
number
patient
cap
due
sp
thirtyon
sampl
posit
sp
typeabl
serotyp
tabl
serotyp
sampl
seri
sp
main
caus
cap
conjug
vaccin
potenti
cover
isol
serotyp
conflict
interest
perch
studi
vaccin
access
center
john
hopkin
bloomberg
school
public
health
baltimor
usa
background
blood
cultur
gold
standard
diagnost
test
pneumococc
pneumonia
factor
potenti
influenc
blood
cultur
posit
examin
pneumonia
etiolog
research
child
health
perch
studi
method
particip
children
mo
african
asian
countri
hospit
sever
sever
pneumonia
blood
cultur
process
autom
system
bottl
incub
day
unless
posit
antibiot
pretreat
assess
serum
bioassay
clinician
report
result
specimen
cultur
date
yield
noncontamin
organ
rang
across
site
yield
streptococcu
pneumonia
pneumonia
posit
rang
antibiot
pretreat
blood
cultur
volum
vari
site
figur
use
multivari
logist
regress
adjust
site
blood
cultur
posit
pneumonia
significantli
associ
sever
pneumonia
ci
hiv
infect
ci
specimen
volum
show
trend
associ
isol
pneumococcu
ci
antibiot
pretreat
show
neg
trend
associ
isol
pneumococcu
ci
conclus
pneumococc
yield
blood
cultur
vari
consider
perch
site
diseas
sever
hivstatu
significantli
associ
pneumococcalspecif
blood
cultur
yield
studi
popul
indic
nonsignific
trend
associ
blood
volum
antibiot
pretreat
conflict
interest
tin
tin
p
h
e
vaccin
pfizer
intern
oper
pari
franc
pfizer
ltd
walton
hill
unit
kingdom
pfizer
hella
ae
athen
greec
background
aim
prevenar
licens
prevent
pneumococc
diseas
replac
review
aim
evalu
impact
pneumonia
western
europ
north
america
method
literatur
review
perform
assess
impact
pneumococc
allcausepneumonia
relat
hospit
healthcar
visit
result
twelv
studi
europ
n
us
n
report
impact
allcaus
pneumonia
hospit
six
also
report
impact
pneumococc
pneumonia
hospit
children
year
reduct
median
median
observ
pneumococc
allcaus
pneumonia
hospit
respect
age
year
reduct
median
report
pneumococc
pneumonia
hospit
wherea
allcaus
pneumonia
hospit
impact
vari
reduct
increas
median
reduct
age
group
median
reduct
rang
rang
pneumococc
allcaus
pneumonia
hospit
respect
conclus
report
impact
vari
age
case
definit
pneumococc
allcausepneumonia
period
compar
particularli
time
introduct
definit
period
gener
reduct
pneumococc
pneumonia
age
group
reduct
allcausepneumonia
clearli
visibl
children
year
conflict
interest
jr
n
cg
r
diseas
branch
center
diseas
control
prevent
atlanta
usa
infecti
diseas
unit
soroka
univers
medic
center
faculti
health
scienc
bengurion
univers
beersheva
israel
background
pneumococc
conjug
vaccin
pcv
import
tool
reduc
burden
pediatr
pneumonia
howev
rel
littl
known
effect
pneumonia
routin
immun
program
israel
introduc
pcv
juli
transit
novemb
method
util
data
populationbas
ongo
surveil
pediatr
pneumonia
gastroenter
larg
hospit
southern
israel
casecontrol
analysi
pcv
effect
pneumonia
case
defin
alveolar
pneumonia
chest
radiograph
children
ageelig
pcv
dose
control
select
children
rotavirusneg
gastroenter
individu
match
case
ethnic
jewishbedouin
birth
date
month
medic
attent
date
month
estim
effect
match
odd
ratio
pcv
vaccin
result
juli
june
case
enrol
surveil
match
control
median
control
per
case
rang
median
age
match
case
month
rang
bedouin
overal
case
control
receiv
pcv
dose
pcv
dose
data
formul
effect
pcv
dose
ci
conclus
pcv
protect
pneumonia
routin
immun
program
israel
result
reflect
combin
effect
analysi
potenti
contribut
vs
ongo
attempt
guid
polici
decis
conflict
interest
cl
jr
mr
c
f
w
ka
jp
institut
universidad
del
vall
de
guatemala
guatemala
citi
guatemala
center
immun
respiratori
diseas
center
diseas
control
prevent
atlanta
usa
center
epidemiolog
ministri
health
guatemala
guatemala
diseas
detect
branch
center
diseas
control
prevent
atlanta
usa
background
streptococcu
pneumonia
lead
caus
pneumonia
worldwid
howev
burden
pneumococc
pneumonia
among
adult
low
middleincom
countri
well
describ
method
analyz
data
two
surveil
site
guatemala
describ
pneumococc
pneumonia
adult
case
defin
posit
pneumococc
urinari
antigen
test
blood
cultur
person
year
age
hospit
signsymptom
respiratori
diseas
evid
acut
infect
calcul
incid
rate
use
censu
data
adjust
incid
account
miss
test
result
healthcar
util
survey
surveil
area
result
among
adult
admit
respiratori
signssymptom
evid
acut
infect
either
urin
test
n
blood
cultur
n
perform
detect
case
pneumococc
pneumonia
posit
urin
six
also
blood
cultur
overal
observ
incid
pneumococc
pneumonia
person
per
year
lowest
rate
among
yearold
highest
among
year
old
adjust
incid
hospit
pneumococc
pneumonia
overal
among
year
old
clear
season
trend
time
incid
overal
inhospit
mortal
conclus
show
import
burden
hospit
pneumococc
pneumonia
adult
particularli
elderli
howev
even
adjust
rate
like
underestim
true
burden
commun
data
provid
use
baselin
measur
indirect
effect
recent
introduct
pneumococc
conjug
vaccin
guatemala
conflict
interest
pk
dk
medicin
bp
koirala
institut
health
scienc
dharan
nepal
background
aim
approxim
global
particul
matter
air
pollut
occur
indoor
develop
world
high
concentr
indoor
air
pollut
lead
number
advers
health
consequ
aim
studi
find
preval
indoor
air
pollutio
effect
human
health
especi
among
women
children
method
descript
cross
section
studi
design
done
hilli
area
dhankuta
district
eastern
nepal
data
collect
pretest
semiquantit
questionnair
interview
observ
checklist
physic
clinic
examin
done
data
enter
excel
program
analyz
spss
result
total
hous
enrol
interview
systemat
major
hindu
live
semipucca
hous
poverti
line
major
peopl
use
biomass
kitchen
fuel
exhaust
outlet
regard
time
spend
kitchen
work
kitchen
hour
hr
health
relat
problem
may
due
indoor
air
pollut
women
work
kitchen
accordingli
found
kind
breathless
cough
produc
phlegm
total
suffer
pneumonia
suffer
bronchiti
suffer
chronic
obstruct
pulmonari
diseas
copd
suffer
bronchial
asthma
conclus
studi
reveal
sever
indoor
air
pollut
around
kind
respiratori
problem
pneumonia
common
conflict
interest
n
k
k
infect
control
prevent
osaka
univers
graduat
school
medicin
osakasuita
japan
clinic
research
infecti
diseas
research
institut
microbi
diseas
osaka
univers
osakasuita
japan
infecti
diseas
surveil
center
nation
institut
infecti
diseas
osakasuita
japan
background
outbreak
pandem
influenza
viru
pdm
caus
high
morbid
mortal
fatal
case
relat
bacteri
coinfect
streptococcu
pneumonia
sp
staphylococcu
pyogen
staphylococcu
aureu
studi
report
secondari
pneumococc
pneumonia
pdm
studi
compar
secondari
pneumococc
pneumonia
mice
pdm
seanon
influenza
viru
nc
method
mice
infect
intranas
pdm
nc
follow
day
later
nasal
infect
sp
hour
pneumococc
infect
lung
blood
sampl
obtain
examin
bacteri
viral
titer
cytokin
express
lung
histopatholog
result
bacteri
densiti
increas
similarli
pdmsp
coinfect
mice
pdm
mice
ncsp
coinfect
mice
nc
mice
compar
nc
mice
pdm
mice
show
higher
level
inflammatori
cytokin
lower
level
antiinflammatori
cytokin
histopatholog
lung
tissu
pdm
mice
antigen
influenza
viru
detect
alveolar
bronchoalveolar
epithelium
contrast
found
bronchoalveolar
epithelium
nc
mice
conclus
data
indic
pdm
invas
lung
provok
sever
inflamm
comparison
nc
contrast
bacteri
load
lung
influenza
infect
compar
result
suggest
enhanc
inflamm
play
critic
role
establish
sever
clinic
manifest
secondari
bacteri
infect
pdm
infect
conflict
interest
lt
ba
kk
ny
infecti
sd
asfendiyarov
kazakh
nation
medic
univers
almati
kazakhstan
sd
asfendiyarov
kazakh
nation
medic
univers
almati
kazakhstan
kazakh
state
sanitarium
inspect
ministri
health
rk
almati
kazakhstan
pneumococc
diseas
seriou
medic
social
problem
mani
countri
world
includ
kazakhstan
intellig
solut
problem
pneumococc
carrier
decreas
larg
number
variou
form
pneumococc
diseas
develop
antibiot
resist
pneumococcu
vaccin
sinc
region
kazakhstan
step
vaccin
pneumococc
diseas
start
activ
implement
throughout
countri
aim
evalu
result
vaccin
pneumococc
diseas
region
kazakhstan
materi
method
analysi
statist
data
pneumococc
diseas
incid
acut
otiti
media
infant
mortal
pneumonia
statist
book
health
republ
kazakhstan
activ
health
care
organ
result
decreas
incid
pneumonia
per
infant
east
kazakhstan
region
accordingli
mangystau
region
incid
acut
otiti
media
also
decreas
east
kazakhstan
region
mangystau
region
time
infant
mortal
pneumonia
per
livebirth
infant
east
kazakstan
region
decreas
mangystau
region
conclus
implement
specif
vaccin
pneumococc
diseas
reduc
infant
child
mortal
diseas
incid
may
also
impact
total
mortal
due
produc
effect
commun
immun
conflict
interest
c
h
c
medicin
seoul
nation
univers
colleg
medicin
seoul
korea
purpos
aim
evalu
sensit
urinari
pneumococc
antigen
test
upa
diagnos
pneumococc
pneumonia
clinic
set
verifi
factor
associ
falseneg
upa
result
method
januari
decemb
adult
patient
admit
pneumococc
pneumonia
enrol
retrospect
sever
communityacquir
pneumonia
cap
assess
score
result
total
patient
includ
studi
one
hundr
sixti
patient
streptococcu
pneumonia
respiratori
specimen
patient
blood
one
patient
pleural
fluid
eightyfour
patient
upa
posit
sensit
test
ci
upa
sensit
patient
pneumococc
bacteremia
wherea
sensit
patient
without
bacteremia
multivari
analysi
falseneg
result
upa
associ
lower
creactiv
protein
crp
level
mgl
lower
score
older
age
underli
lung
diseas
absenc
cerebrovascular
accid
conclus
upa
show
compar
low
sensit
microbiolog
proven
cap
older
age
underli
lung
diseas
absenc
cerebrovascular
accid
lower
crp
level
lower
score
independ
associ
falseneg
result
upa
conflict
interest
q
j
j
j
l
z
j
g
school
public
health
fudan
univers
shanghai
china
soochow
univers
affili
children
hospit
suzhou
china
diseas
suzhou
center
diseas
control
prevent
suzhou
china
soochow
univers
affili
children
hospit
suzhou
china
chines
center
diseas
control
prevent
beij
china
offic
us
center
diseas
control
prevent
beij
china
background
aim
sever
acut
respiratori
infect
sari
lead
caus
hospit
children
studi
learn
etiolog
clinic
characterist
sari
chines
children
method
sinc
march
surveil
studi
sari
children
conduct
soochow
univers
affili
children
hospit
nasopharyng
aspir
blood
pleural
effus
bacteri
cultur
realtim
pcr
rtpcr
direct
immunofluoresc
antigen
test
viru
use
identifi
possibl
pathogen
result
march
june
total
children
year
includ
male
mean
age
year
children
proven
pneumonia
combin
test
identifi
least
one
pathogen
case
common
pathogen
streptococcu
pneumonia
respiratori
syncyti
viru
influenza
viru
haemophilu
influenza
median
length
hospit
stay
treatment
hospit
receiv
antibiot
receiv
antivir
agent
glucocorticoid
requir
oxygen
treatment
refer
icu
mean
cost
hospit
around
us
children
rsv
infect
significantli
younger
influenza
p
sp
infect
p
compar
nonsp
infect
children
sp
infect
children
significantli
higher
hospit
cost
p
longer
hospit
stay
p
conclus
sp
rsv
influenza
common
etiolog
agent
childhood
sari
suzhou
china
find
underscor
high
burden
hospit
sari
young
children
conflict
interest
